Value Of Stent-coating Drugs Questioned

New research about possible additive drugs to help reduce in-stent restenosis was presented at the American College of Cardiology's Innovation in Intervention: i2 Summit in New Orleans, La.  The research will also appear in the March 27 print issue of the Journal of the American College of Cardiology.

Past research has shown that estradiol promotes rapid reendothelialization of coronary stents in animals and can effectively moderate the release of rapamycin from the coated stent surface. Researchers hypothesized that estradiol might improve the efficacy profile of rapamycin-coated stents. A total of 500 patients undergoing PCIs in a native coronary vessel were enrolled in the ISAR-PEACE study -- Intracoronary Stenting and Angiographic Restenosis: Promote EndotheliAl Cells with Estradiol. All enrolled patients were randomly assigned to receive a polymer-free, 17ƒÒ estradiolvalerat plus rapamycin-eluting stent or a polymer-free, rapamycin-eluting stent. The stent platform was the ISAR stent with a rough surface, the value of which has been established by several previous studies. A specifically designed rough surface may increase the drug-storing capacity of stents.

All patients received dual-antiplatelet therapy with ASA and clopidogrel for a minimum of six months, were scheduled for a re-angiography at 6-8 months and were contacted at 30 days and at one year for the assessment of the clinical status. Patients with ST-elevation myocardial infarction (MI), cardiogenic shock or a left main disease were excluded from the trial. The primary endpoint of the trial was in-stent late lumen loss. Secondary end points were binary angiographic restenosis, target lesion revascularization, combined incidence of death or MI and the incidence of stent thrombosis.

Researchers found no significant differences between the 17ƒÒ estradiolvalerat plus rapamycin¡Veluting stent group and the rapamycin-eluting stent group according to late lumen loss (0.52 mm vs. 0.51 mm), the incidence of binary angiographic restenosis (17.6% vs. 16.9%), the incidence of target lesion revascularization (14.3% vs. 13.2%), the combined incidence of death and myocardial infarction (7.9% vs. 8.0%) and the incidence of stent thrombosis (0.8% vs. 1.2%).

"The ISAR-PEACE trial represents the largest clinical experience with 17-ƒÒ-estradiol-eluting stents and the first clinical trial to assess a combination of drugs such as estradiol and rapamycin in the settings of DES technology," said Julinda Mehilli, M.D., of Deutsches Herzzentrum, Munich, Germany, and lead author of the study. ¡§The trial shows that adding estradiol to a polymer-free rapamycin-eluting stent is not associated with any measurable benefit during the first year after PCI. However, further research is needed to fully determine the role of estradiol as a drug used for stent coating."

Dr. Mehilli will present the results of the "Intracoronary Stenting and Angiographic Restenosis: Promote EndotheliAl Cells with Estradiol (ISAR-PEACE)" study at the American College of Cardiology's Innovation in Intervention: i2 Summit.